Paul W.H.I. Parren

31.7k total citations · 11 hit papers
261 papers, 23.3k citations indexed

About

Paul W.H.I. Parren is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Paul W.H.I. Parren has authored 261 papers receiving a total of 23.3k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Radiology, Nuclear Medicine and Imaging, 115 papers in Immunology and 77 papers in Oncology. Recurrent topics in Paul W.H.I. Parren's work include Monoclonal and Polyclonal Antibodies Research (173 papers), Glycosylation and Glycoproteins Research (48 papers) and Immune Cell Function and Interaction (48 papers). Paul W.H.I. Parren is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (173 papers), Glycosylation and Glycoproteins Research (48 papers) and Immune Cell Function and Interaction (48 papers). Paul W.H.I. Parren collaborates with scholars based in Netherlands, United States and Denmark. Paul W.H.I. Parren's co-authors include Dennis R. Burton, Jan G. J. van de Winkel, Janine Schuurman, Aran F. Labrijn, Wim K. Bleeker, Frank J. Beurskens, Erica Ollmann Saphire, John P. Moore, Maarten L. Janmaat and Ann J. Hessell and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Paul W.H.I. Parren

257 papers receiving 22.7k citations

Hit Papers

Efficient Neutralization of Primary Isolates of HIV-1 by ... 1987 2026 2000 2013 1994 2019 2001 2010 1987 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
    1994 938 citations Dennis R. Burton, Paul W.H.I. Parren et al. profile →
  2. Bispecific antibodies: a mechanistic review of the pipeline
    2019 887 citations Aran F. Labrijn, Maarten L. Janmaat et al. Nature Reviews Drug Discovery profile →
  3. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design
    2001 749 citations Paul W.H.I. Parren, Dennis R. Burton et al. profile →
  4. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
    2010 746 citations Tom Vink, Matthias Peipp et al. profile →
  5. The Drosophila homology of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless
    1987 744 citations Paul W.H.I. Parren et al. profile →
  6. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
    2007 707 citations Janine Schuurman, Wim K. Bleeker et al. profile →
  7. Fc receptor but not complement binding is important in antibody protection against HIV
    2007 693 citations Carin E.G. Havenith, Frank J. Beurskens et al. profile →
  8. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41
    2001 632 citations Aran F. Labrijn, Dennis R. Burton et al. Journal of Virology profile →
  9. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
    2014 568 citations Frank J. Beurskens, Rob N. de Jong et al. profile →
  10. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro
    2001 530 citations Paul W.H.I. Parren, Dennis R. Burton et al. Journal of Virology profile →
  11. Avidity in antibody effector functions and biotherapeutic drug design
    2022 141 citations Janine Schuurman, Paul W.H.I. Parren et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul W.H.I. Parren Netherlands 86 9.6k 9.2k 8.1k 6.0k 4.9k 261 23.3k
Pamela J. Björkman United States 79 14.6k 1.5× 7.4k 0.8× 9.7k 1.2× 3.6k 0.6× 1.8k 0.4× 245 29.0k
Ellis L. Reinherz United States 96 24.2k 2.5× 11.1k 1.2× 9.2k 1.1× 2.5k 0.4× 5.5k 1.1× 392 36.0k
Barton F. Haynes United States 90 16.7k 1.7× 4.7k 0.5× 8.5k 1.1× 14.9k 2.5× 2.1k 0.4× 432 34.7k
Jeffrey V. Ravetch United States 115 29.6k 3.1× 18.4k 2.0× 15.6k 1.9× 1.9k 0.3× 7.4k 1.5× 268 47.2k
Michel C. Nussenzweig United States 136 39.4k 4.1× 7.8k 0.9× 20.1k 2.5× 8.7k 1.5× 7.7k 1.6× 379 61.3k
Michael S. Neuberger United Kingdom 74 10.7k 1.1× 5.7k 0.6× 10.2k 1.3× 2.4k 0.4× 2.0k 0.4× 165 20.0k
Peter C. L. Beverley United Kingdom 71 11.8k 1.2× 2.9k 0.3× 3.8k 0.5× 3.6k 0.6× 2.4k 0.5× 297 19.0k
Louis J. Picker United States 77 16.9k 1.8× 1.8k 0.2× 4.7k 0.6× 8.0k 1.3× 3.4k 0.7× 199 29.2k
Yvette van Kooyk Netherlands 89 17.6k 1.8× 2.5k 0.3× 10.7k 1.3× 3.1k 0.5× 2.2k 0.4× 324 29.1k
George Janossy United Kingdom 77 9.2k 1.0× 2.7k 0.3× 3.3k 0.4× 2.2k 0.4× 1.9k 0.4× 298 18.9k

Countries citing papers authored by Paul W.H.I. Parren

Since Specialization
Citations

This map shows the geographic impact of Paul W.H.I. Parren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul W.H.I. Parren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul W.H.I. Parren more than expected).

Fields of papers citing papers by Paul W.H.I. Parren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul W.H.I. Parren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul W.H.I. Parren. The network helps show where Paul W.H.I. Parren may publish in the future.

Co-authorship network of co-authors of Paul W.H.I. Parren

This figure shows the co-authorship network connecting the top 25 collaborators of Paul W.H.I. Parren. A scholar is included among the top collaborators of Paul W.H.I. Parren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul W.H.I. Parren. Paul W.H.I. Parren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bovenkamp, Fleur S. van de, Jos Pool, Cynthia S. M. Kramer, et al.. (2023). Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation. Proceedings of the National Academy of Sciences. 120(50). e2310666120–e2310666120. 9 indexed citations
2.
Kuipers, Annemarie, Jürgen Strasser, Maartje Ruyken, et al.. (2021). C1q binding to surface-bound IgG is stabilized by C1r 2 s 2 proteases. Proceedings of the National Academy of Sciences. 118(26). 39 indexed citations
3.
Vergoossen, Dana L.E., Jaap J. Plomp, Christoph Gstöttner, et al.. (2021). Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proceedings of the National Academy of Sciences. 118(13). 32 indexed citations
4.
Overdijk, Marije B., Kristin Strumane, Frank J. Beurskens, et al.. (2020). Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Molecular Cancer Therapeutics. 19(10). 2126–2138. 36 indexed citations
5.
Weerdt, Iris de, Roeland Lameris, George L. Scheffer, et al.. (2020). A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research. 9(1). 50–61. 32 indexed citations
6.
Labrijn, Aran F., Maarten L. Janmaat, Janice M. Reichert, & Paul W.H.I. Parren. (2019). Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery. 18(8). 585–608. 887 indexed citations breakdown →
7.
Goeij, Bart E.C.G. de, Tom Vink, Esther C.W. Breij, et al.. (2016). Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63. Molecular Cancer Therapeutics. 15(11). 2688–2697. 101 indexed citations
8.
Matas‐Céspedes, Alba, Vanina Rodríguez, Neus Villamor, et al.. (2016). The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(6). 1493–1505. 45 indexed citations
9.
Flynn, Michael, Francesca Zammarchi, Peter Tyrer, et al.. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics. 15(11). 2709–2721. 85 indexed citations
10.
Moores, Sheri L., Mark L. Chiu, Barbara S. Bushey, et al.. (2016). A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors. Cancer Research. 76(13). 3942–3953. 188 indexed citations
11.
Goeij, Bart E.C.G. de, David Satijn, Richard Wubbolts, et al.. (2015). High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 14(5). 1130–1140. 78 indexed citations
12.
Riedl, Thilo, et al.. (2015). High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe. SLAS DISCOVERY. 21(1). 12–23. 32 indexed citations
13.
14.
Larrick, James W., Paul W.H.I. Parren, James S. Huston, et al.. (2014). Antibody engineering and therapeutics conference. mAbs. 6(5). 1115–1123. 2 indexed citations
15.
Breij, Esther C.W., Bart E.C.G. de Goeij, Sandra Verploegen, et al.. (2013). An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. Cancer Research. 74(4). 1214–1226. 166 indexed citations
16.
Bangsgaard, Nannie, Mischa Houtkamp, Danita H. Schuurhuis, et al.. (2012). Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor. PLoS ONE. 7(6). e39706–e39706. 25 indexed citations
17.
Boross, Péter, J.H. Marco Jansen, Simone de Haij, et al.. (2011). The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 96(12). 1822–1830. 55 indexed citations
18.
Dechant, Michael, Sven Berger, Matthias Peipp, et al.. (2008). Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies. Cancer Research. 68(13). 4998–5003. 132 indexed citations
19.
Bueren, Jeroen J. Lammerts van, Wim K. Bleeker, Henrik O. Bøgh, et al.. (2006). Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action. Cancer Research. 66(15). 7630–7638. 102 indexed citations
20.
Parren, Paul W.H.I., et al.. (2002). Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. Journal of Virology. 76(12). 6408–6412. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pamela J. Björkman Breakdown of academic impact, for papers by Ellis L. Reinherz Breakdown of academic impact, for papers by Barton F. Haynes Breakdown of academic impact, for papers by Jeffrey V. Ravetch Breakdown of academic impact, for papers by Michel C. Nussenzweig Breakdown of academic impact, for papers by Michael S. Neuberger Breakdown of academic impact, for papers by Peter C. L. Beverley Breakdown of academic impact, for papers by Louis J. Picker Breakdown of academic impact, for papers by Yvette van Kooyk Breakdown of academic impact, for papers by George Janossy
Rankless by CCL
2026